This study provides a novel immunotherapy combined with anti-angiogenic treatment strategy for patients with melanoma brain metastases, suggesting that the combination of PD-1 inhibitors and VEGF inhibitors may enhance intracranial antitumor activity and improve survival, offering direct evidence for the design of subsequent clinical trials.
Literature Overview
The article titled 'A phase 2 trial of pembrolizumab in combination with bevacizumab for untreated melanoma brain metastases,' published in the 'Journal of Clinical Oncology,' systematically investigates the efficacy and safety of pembrolizumab combined with bevacizumab in patients with untreated melanoma brain metastases. The study adopts a multicenter, single-arm design aimed at evaluating the intracranial objective response rate of this combination regimen and exploring potential biomarkers. The results indicate that this regimen not only demonstrates high intracranial and systemic response rates but also has a manageable safety profile, laying a solid foundation for future research.Background Knowledge
Brain metastases are a common and often fatal complication in patients with advanced melanoma. Although traditional radiotherapy can locally control lesions, it fails to prevent the emergence of new metastases and carries the risk of neurotoxicity. Despite the significant efficacy of immune checkpoint inhibitors such as PD-1 inhibitors in systemic disease, their penetration and functionality within the central nervous system (CNS) remain limited. Currently, the intracranial response rate of PD-1 monotherapy in melanoma brain metastases is approximately 20%–26%, and some patients develop radiation necrosis (RN), limiting its long-term use. Anti-angiogenic agents such as VEGF inhibitors (e.g., bevacizumab) can not only improve immune cell infiltration by normalizing tumor vasculature but also reduce peritumoral edema and treat RN, theoretically enhancing the antitumor effects of PD-1 inhibitors. Therefore, dual blockade of PD-1 and VEGF has emerged as a key strategy to overcome the immunosuppressive microenvironment and improve intracranial efficacy, yet lacks prospective clinical data. This study is based on this mechanistic hypothesis, exploring the clinical activity of pembrolizumab combined with bevacizumab in patients with untreated melanoma brain metastases, thereby filling an evidence gap in this field.
Research Methods and Experiments
The study enrolled 37 asymptomatic patients with untreated melanoma brain metastases who had not previously received PD-1 inhibitor therapy. Patients received pembrolizumab (200 mg every 3 weeks) in combination with bevacizumab (7.5 mg/kg every 3 weeks) for four cycles, followed by pembrolizumab monotherapy up to 24 months or until disease progression. The primary endpoint was intracranial objective response rate (BMRR), and secondary endpoints included extracranial response rate, progression-free survival (PFS), overall survival (OS), and safety. Imaging assessments followed modified RECIST 1.1 criteria and were independently evaluated by neuroradiologists blinded to treatment. Additionally, plasma cytokine levels and tumor tissue immunohistochemistry were analyzed to explore potential predictive biomarkers. This design effectively controlled for confounding effects of local therapy on efficacy assessment while directly testing the hypothesis that vascular normalization enhances immunotherapy through the combination strategy.Key Conclusions and Perspectives
Research Significance and Prospects
This study establishes a new clinical pathway for treating melanoma brain metastases, supporting the consideration of PD-1 and VEGF combination strategies as first-line therapy. Its impressive long-term survival data may redefine standard treatment approaches. Future studies should conduct randomized phase III trials directly comparing this combination regimen with standard dual immunotherapy to confirm its superiority. Additionally, patient stratification strategies based on biomarkers are worth exploring to achieve precision medicine.
Conclusion
This study establishes significant clinical activity and favorable safety of pembrolizumab combined with bevacizumab in patients with untreated melanoma brain metastases. With an intracranial response rate of 54.1% and a median overall survival of 4.3 years, it challenges existing treatment paradigms and offers new hope for patients. From bench to bedside, this research validates the theoretical basis of synergy between anti-angiogenesis and immunotherapy, advancing the field from single checkpoint blockade to multi-target combination interventions. Notably, this regimen avoids the high toxicity of dual immunotherapy, reducing treatment-related risks and making it more suitable for elderly or comorbid patients. In the future, personalized treatment strategies incorporating biomarkers such as CD34 and angiopoietin-2 may further enhance efficacy. This study not only provides a new therapeutic option for patients with melanoma brain metastases but also offers important insights for immunotherapy combinations in other solid tumor brain metastases, representing a significant step forward in the development of precision oncology.
